Warner Chilcott Ltd. (WCRX) reported second-quarter results Friday. The company’s GAAP net income came in at $56 million, or 22 cents per share, recording a robust 66.7% growth over the prior year quarter. Excluding certain non-cash items, earnings per share of 44 cents topped the Zacks Consensus Estimate by 5 cents, or nearly 13%. Warner Chilcott, a leading specialty pharmaceutical company focused on women's healthcare and dermatology segments in the U.S. market, has manufacturing facilities in Puerto Rico and Northern Ireland. The Rockaway, NJ-based company’s quarterly revenues expanded 7.1% year over year to $250.8 million, primarily driven by the sales of Doryx, Loestrin 24 Fe and Estrace cream products. Sales of Oral Contraceptive products rose 5.6% year over year to $75.5 million. The growth was driven by the company’s flagship product, Loestrin 24 Fe, which grew 15% to $58 million due to higher average selling prices ...

Warner Chilcott Ltd.'s (WCRX) announced first-quarter EPS, excluding items, of 39 cents, which matched the consensus.

Revenues expanded 7% to $246 million, primarily due to the growth of Doryx, Loestrin 24 FE and Estrace Cream.

Warner Chillcott indicated that it continues to expect fiscal 2009 revenues to range between $1.015 billion and $1.025 billion.

The developer of woman healthcare products also affirmed full-year earnings guidance of $1.55 to $1.60 per share, excluding items, which is in-line with the $1.59 consensus derived from 12 analysts.

WCRX, Zacks #3 Rank ("Hold") stock, is about breakeven today with volume of approximately 616,000, which is lower than the average daily volume of about 1.02 million.

"WCRX" Free Stock Analysis: Buy? Sell? Hold?Zacks Investment Research